• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

技术进步与无保护左主干病变患者经皮冠状动脉介入治疗的临床结局改善相关。

Technological Advances Are Associated With Better Clinical Outcomes of Percutaneous Coronary Intervention in Patients With Unprotected Left Main Disease.

机构信息

Department of Cardiology, Cardiometabolic Medicine Center, Coronary Heart Disease Center, Fuwai Hospital, National Center for Cardiovascular Diseases Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China.

State Key Laboratory of Cardiovascular Disease Beijing China.

出版信息

J Am Heart Assoc. 2024 Aug 20;13(16):e033929. doi: 10.1161/JAHA.123.033929. Epub 2024 Aug 9.

DOI:10.1161/JAHA.123.033929
PMID:39119974
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11963951/
Abstract

BACKGROUND

Few large-scale studies have evaluated the effectiveness of percutaneous coronary intervention (PCI) technological advances in the treatment of patients with unprotected left main coronary artery disease (LM-CAD). We aim to identify independent factors that affect the prognosis of PCI in patients with unprotected LM-CAD and to assess the impact of PCI technological advances on long-term clinical outcomes.

METHODS AND RESULTS

A total of 4512 consecutive patients who underwent unprotected LM-CAD PCI at Fuwai Hospital from 2004 to 2016 were enrolled. Multivariable Cox proportional hazards model was used to identify which techniques can independently affect the incidence of major adverse cardiac events (MACEs; a composite of cardiac death, myocardial infarction, or target vessel revascularization). The incidence of 3-year MACEs was 9.0% (406/4512). Four new PCI techniques were identified as the independent protective factors of MACEs, including second-generation drug-eluting stents (hazard ratio [HR], 0.61 [95% CI, 0.37-0.99]), postdilatation (HR, 0.75 [95% CI, 0.59-0.94]), final kissing balloon inflation (HR, 0.78 [95% CI, 0.62-0.99]), and using intravascular ultrasound (HR, 0.78 [95% CI, 0.63-0.97]). The relative hazard of 3-year MACEs was reduced by ≈50% with use of all 4 techniques compared with no technique use (HR, 0.53 [95% CI, 0.32-0.87]).

CONCLUSIONS

PCI technological advances including postdilatation, second-generation drug-eluting stent, final kissing balloon inflation, and intravascular ultrasound guidance were associated with improved clinical outcomes in patients who underwent unprotected LM-CAD PCI.

摘要

背景

鲜有大规模研究评估经皮冠状动脉介入治疗(PCI)技术进步在治疗无保护左主干冠状动脉疾病(LM-CAD)患者中的效果。我们旨在确定影响无保护 LM-CAD 患者 PCI 预后的独立因素,并评估 PCI 技术进步对长期临床结局的影响。

方法和结果

共纳入 2004 年至 2016 年在阜外医院接受无保护 LM-CAD PCI 的 4512 例连续患者。采用多变量 Cox 比例风险模型确定哪些技术可独立影响主要不良心脏事件(MACE;心脏死亡、心肌梗死或靶血管血运重建的复合终点)的发生率。3 年 MACE 发生率为 9.0%(406/4512)。确定了 4 种新的 PCI 技术是 MACE 的独立保护因素,包括第二代药物洗脱支架(风险比 [HR],0.61 [95%CI,0.37-0.99])、后扩张(HR,0.75 [95%CI,0.59-0.94])、最终对吻球囊扩张(HR,0.78 [95%CI,0.62-0.99])和血管内超声(HR,0.78 [95%CI,0.63-0.97])。与不使用任何技术相比,使用所有 4 种技术可使 3 年 MACE 的相对危险度降低约 50%(HR,0.53 [95%CI,0.32-0.87])。

结论

包括后扩张、第二代药物洗脱支架、最终对吻球囊扩张和血管内超声指导在内的 PCI 技术进步与接受无保护 LM-CAD PCI 的患者临床结局改善相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6957/11963951/d153cf0cd1eb/JAH3-13-e033929-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6957/11963951/8265bcb4e0dd/JAH3-13-e033929-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6957/11963951/c2eb231690ef/JAH3-13-e033929-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6957/11963951/a2c72adc36fe/JAH3-13-e033929-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6957/11963951/d153cf0cd1eb/JAH3-13-e033929-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6957/11963951/8265bcb4e0dd/JAH3-13-e033929-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6957/11963951/c2eb231690ef/JAH3-13-e033929-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6957/11963951/a2c72adc36fe/JAH3-13-e033929-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6957/11963951/d153cf0cd1eb/JAH3-13-e033929-g004.jpg

相似文献

1
Technological Advances Are Associated With Better Clinical Outcomes of Percutaneous Coronary Intervention in Patients With Unprotected Left Main Disease.技术进步与无保护左主干病变患者经皮冠状动脉介入治疗的临床结局改善相关。
J Am Heart Assoc. 2024 Aug 20;13(16):e033929. doi: 10.1161/JAHA.123.033929. Epub 2024 Aug 9.
2
Long-term clinical outcomes after percutaneous coronary intervention for ostial/mid-shaft lesions versus distal bifurcation lesions in unprotected left main coronary artery: the DELTA Registry (drug-eluting stent for left main coronary artery disease): a multicenter registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment.经皮冠状动脉介入治疗开口/中段病变与无保护左主干冠状动脉分叉病变的长期临床结局:DELTA 注册研究(左主干冠状动脉疾病药物洗脱支架):一项多中心注册研究,评估经皮冠状动脉介入治疗与冠状动脉旁路移植术治疗左主干的疗效。
JACC Cardiovasc Interv. 2013 Dec;6(12):1242-9. doi: 10.1016/j.jcin.2013.08.005.
3
The anatomic- and clinical-based NERS (new risk stratification) score II to predict clinical outcomes after stenting unprotected left main coronary artery disease: results from a multicenter, prospective, registry study.基于解剖和临床的 NERS(新风险分层)评分 II 预测无保护左主干冠状动脉疾病支架置入后的临床结局:来自多中心、前瞻性登记研究的结果。
JACC Cardiovasc Interv. 2013 Dec;6(12):1233-41. doi: 10.1016/j.jcin.2013.08.006. Epub 2013 Nov 13.
4
Major Predictors of Long-Term Clinical Outcomes After Percutaneous Coronary Intervention for Coronary Bifurcation Lesions With 2-Stent Strategy: Patient-Level Analysis of the Korean Bifurcation Pooled Cohorts.经皮冠状动脉介入治疗冠状动脉分叉病变双支架策略的长期临床结局的主要预测因素:韩国分叉队列的患者水平分析。
JACC Cardiovasc Interv. 2016 Sep 26;9(18):1879-86. doi: 10.1016/j.jcin.2016.06.049. Epub 2016 Aug 31.
5
Impact of Operator Experience and Volume on Outcomes After Left Main Coronary Artery Percutaneous Coronary Intervention.术者经验和手术量对左主干经皮冠状动脉介入治疗结局的影响。
JACC Cardiovasc Interv. 2016 Oct 24;9(20):2086-2093. doi: 10.1016/j.jcin.2016.08.011.
6
The DELTA 2 Registry: A Multicenter Registry Evaluating Percutaneous Coronary Intervention With New-Generation Drug-Eluting Stents in Patients With Obstructive Left Main Coronary Artery Disease.DELTA 2 注册研究:一项多中心注册研究,旨在评估新型药物洗脱支架经皮冠状动脉介入治疗伴左主干病变的患者。
JACC Cardiovasc Interv. 2017 Dec 11;10(23):2401-2410. doi: 10.1016/j.jcin.2017.08.050.
7
Ten-Year Outcomes After Drug-Eluting Stents Versus Coronary Artery Bypass Grafting for Left Main Coronary Disease: Extended Follow-Up of the PRECOMBAT Trial.药物洗脱支架与冠状动脉旁路移植术治疗左主干病变的 10 年结果:PRECOMBAT 试验的扩展随访。
Circulation. 2020 May 5;141(18):1437-1446. doi: 10.1161/CIRCULATIONAHA.120.046039. Epub 2020 Mar 30.
8
B-Type Natriuretic Peptide Assessment in Patients Undergoing Revascularization for Left Main Coronary Artery Disease: Analysis From the EXCEL Trial.B 型利钠肽评估在左主干冠状动脉疾病血运重建患者中的应用:来自 EXCEL 试验的分析。
Circulation. 2018 Jul 31;138(5):469-478. doi: 10.1161/CIRCULATIONAHA.118.033631.
9
Impact of coronary anatomy and stenting technique on long-term outcome after drug-eluting stent implantation for unprotected left main coronary artery disease.药物洗脱支架置入治疗无保护左主干冠状动脉疾病后,冠状动脉解剖结构和支架技术对长期预后的影响。
JACC Cardiovasc Interv. 2014 Jan;7(1):29-36. doi: 10.1016/j.jcin.2013.08.013. Epub 2013 Dec 11.
10
Coronary Artery Bypass Surgery Versus Drug-Eluting Stent Implantation for Left Main or Multivessel Coronary Artery Disease: A Meta-Analysis of Individual Patient Data.冠状动脉旁路移植术与药物洗脱支架置入术治疗左主干或多支冠状动脉疾病:一项个体患者数据的荟萃分析。
JACC Cardiovasc Interv. 2016 Dec 26;9(24):2481-2489. doi: 10.1016/j.jcin.2016.10.008.

引用本文的文献

1
A Systematic Review of risk factors for major adverse cardiovascular events in patients with coronary heart disease who underwent percutaneous coronary intervention.经皮冠状动脉介入治疗的冠心病患者主要不良心血管事件危险因素的系统评价
Front Physiol. 2025 Apr 9;16:1514585. doi: 10.3389/fphys.2025.1514585. eCollection 2025.

本文引用的文献

1
2022 Joint ESC/EACTS review of the 2018 guideline recommendations on the revascularization of left main coronary artery disease in patients at low surgical risk and anatomy suitable for PCI or CABG.2022 年 ESC/EACTS 联合对 2018 年指南建议的回顾:低手术风险且适合 PCI 或 CABG 解剖结构的左主干冠状动脉疾病患者的血运重建。
Eur Heart J. 2023 Nov 1;44(41):4310-4320. doi: 10.1093/eurheartj/ehad476.
2
Left main bifurcation stenting: impact of residual ischaemia on cardiovascular mortality.左主干分叉病变支架置入术:残余缺血对心血管死亡率的影响。
Eur Heart J. 2023 Nov 1;44(41):4324-4336. doi: 10.1093/eurheartj/ehad318.
3
Intravascular Imaging-Guided or Angiography-Guided Complex PCI.
血管内影像学指导或血管造影指导下的复杂 PCI。
N Engl J Med. 2023 May 4;388(18):1668-1679. doi: 10.1056/NEJMoa2216607. Epub 2023 Mar 5.
4
New Insights Into Long- Versus Short-Term Dual Antiplatelet Therapy Duration in Patients After Stenting for Left Main Coronary Artery Disease: Findings From a Prospective Observational Study.左主干冠状动脉疾病患者支架置入术后长程与短程双联抗血小板治疗时间的新认识:一项前瞻性观察研究的结果。
Circ Cardiovasc Interv. 2022 Jun;15(6):e011536. doi: 10.1161/CIRCINTERVENTIONS.121.011536. Epub 2022 May 18.
5
Differential Effects of Newer-Generation Ultrathin-Strut Versus Thicker-Strut Drug-Eluting Stents in Chronic and Acute Coronary Syndromes.新一代超薄支架与厚壁支架药物洗脱支架在慢性和急性冠状动脉综合征中的差异效应。
JACC Cardiovasc Interv. 2021 Nov 22;14(22):2461-2473. doi: 10.1016/j.jcin.2021.09.028.
6
Implications of Periprocedural Myocardial Biomarker Elevations and Commonly Used MI Definitions After Left Main PCI.左主干 PCI 术后围术期心肌生物标志物升高及常用 MI 定义的意义。
JACC Cardiovasc Interv. 2021 Aug 9;14(15):1623-1634. doi: 10.1016/j.jcin.2021.05.006.
7
Percutaneous coronary intervention for bifurcation coronary lesions: the 15 consensus document from the European Bifurcation Club.经皮冠状动脉介入治疗分叉病变:来自欧洲分叉俱乐部的 15 项共识文件。
EuroIntervention. 2021 Mar 19;16(16):1307-1317. doi: 10.4244/EIJ-D-20-00169.
8
Intravascular ultrasound to guide left main stem intervention: a NOBLE trial substudy.血管内超声指导左主干介入治疗:NOBLE 试验子研究。
EuroIntervention. 2020 Jun 25;16(3):201-209. doi: 10.4244/EIJ-D-19-01003.
9
Impact of Kissing Balloon in Patients Treated With Ultrathin Stents for Left Main Lesions and Bifurcations: An Analysis From the RAIN-CARDIOGROUP VII Study.左主干病变和分叉病变患者应用超薄支架治疗中 Kissing Balloon 的影响:来自 RAIN-CARDIOGROUP VII 研究的分析。
Circ Cardiovasc Interv. 2020 Mar;13(3):e008325. doi: 10.1161/CIRCINTERVENTIONS.119.008325. Epub 2020 Feb 27.
10
Impact of SYNTAX Score on 10-Year Outcomes After Revascularization for Left Main Coronary Artery Disease.SYNTAX 评分对左主干冠状动脉疾病血运重建后 10 年结局的影响。
JACC Cardiovasc Interv. 2020 Feb 10;13(3):361-371. doi: 10.1016/j.jcin.2019.10.020.